Studies

Below is a list of the ongoing clinical research trials in the Department of Dermatology and Dermatologic Surgery:

Atopic Dermatitis

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients with Moderate to Severe Atopic Dermatitis  

  • Population: Patients aged eighteen to fifty five years old
  • Study Condition: Moderate to severe atopic dermatitis
  • Study Design: The main purpose of this study is to learn whether Lebrikizumab could impact how effective certain vaccines may be and how effective and safe the study drug is in patients with moderate-to-severe AD compared with placebo. A placebo is an inactive material that looks like the study drug but does not contain any active study drug. The study duration is approximately 32 weeks, and participants will need to come to the study center at least 7 to 11 times over this period. This study will also include 2 vaccines commonly used in adults with moderate-to-severe AD: meningococcal vaccines (MCV) and tetanus, diphtheria, and pertussis (Tdap).
  • Subjects may be reimbursed for study related travel expenses.

A Study to Investigate the Effectiveness and Safety of ARQ-151 Cream 0.15% in Subjects with Atopic Dermatitis

  • Population: Participants aged six and older
  • Study Condition: Mild to moderate eczema
  • Study Design: This is a four-week placebo-controlled study. Participants will be randomly chosen to either receive ARQ-151 or a vehicle cream. The vehicle cream or placebo is a “dummy” cream that is made from the same base product that is used to make ARQ-151, but it does not contain any active study drug. Participants will apply the ARQ-151 or vehicle once every day for one month.
  • Compensation may be provided  

A Study to Investigate the Efficacy and Safety of ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis

  • Population: Patients aged two to five years old
  • Study Condition: Mild to moderate eczema
  • Study Design: This is a four-week placebo-controlled study. Participants will be randomly chosen to either receive ARQ-151 or a vehicle cream. The vehicle cream or placebo is a “dummy” cream that is made from the same base product that is used to make ARQ-151, but it does not contain any active study drug. Participants will apply the ARQ-151 or vehicle creams once every day for one month.
  • Compensation may be provided

A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Moderate to Severe Atopic Dermatitis

  • Population: Patients aged twelve years and older
  • Study Condition: Moderate to severe atopic dermatitis
  • Study Design: This study can last up to 116 weeks. Participants will receive injections of nemolizumab every four weeks for a treatment period of 104 weeks.
  • Compensation is provided for time and travel

Topical Ruxolitinib Evaluation in Atopic Dermatitis

  • Population: Patients aged two to eleven years old
  • Study Condition: Mild to moderate atopic dermatitis
  • Study Design: The purpose of this research study is to determine if an investigational cream, ruxolitinib cream (0.75% and 1.5% strengths), is safe and effective to treat Atopic Dermatitis. In this study, ruxolitinib cream will be compared to a “vehicle cream.” The vehicle cream looks like the ruxolitinib cream but contains no ruxolitinib. This study can last up to 55 weeks. For the first 8 weeks participants will be randomly assigned to receive either the ruxolitinib cream or vehicle cream. For the following 44 weeks participants will receive the ruxolitinib cream.
  • Compensation will be provided

Prurigo Nodularis 

A Study to Assess the Efficacy and Safety in Prurigo Nodularis (PN) With Nalbuphine ER Tablets for Pruritus Relief Through Itch Scratch Modulation

  • Population: Patients aged eighteen years and older
  • Study Condition: Generalized prurigo nodularis (having at least ten prurigo nodules in two or more distinct anatomical locations on the body)
  • Study Design: Sponsored by Trevi Therapeutics this study is to evaluate Nalbuphine ER tablets, an opioid acting as an antagonist at the mu receptor and agonist at the kappa receptor, deeming it a non-controlled substance developed to alleviate itch. The total length of the study is 56 weeks. During the first fourteen weeks, patients will be randomized 1:1 to receive either Nalbuphine ER or placebo. This will be followed by a 38 week open label period where patients will be guaranteed to receive Nalbuphine ER tablets.
  • Compensation is provided

A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of an Investigational Drug in Reducing Pruritus in Subjects with Prurigo Nodularis

  • Population: Patients aged eighteen to eighty years old
  • Study Condition: Moderate to severe prurigo nodularis (at least twenty nodules in two or more distinct anatomical locations on the body)
  • Study Design: Participants will be randomly assigned to receive different dosing regimens of the investigational drug or a “dummy” substance that has no active drug in it but looks exactly like the investigation drug. This study will last up to one year.
  • The investigational drug or “dummy” substance will be injected under the skin for a treatment period, followed by an open-label extension period where the investigational drug will be provided for the remainder of the study participation period.
  • Compensation is provided

Lamellar Ichthyosis 

Please check back for upcoming lamellar ichthyosis studies  

Psoriasis 

A  Phase 3, Randomized, Active-controlled Study of Risankizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis

  • Population: Individuals aged twelve to seventeen years old
  • Study Condition: Moderate to severe plaque psoriasis
  • Study Design: The purpose of this study is to evaluate the pharmacokinetics (how the study drug moves through the body), safety, and effectiveness of investigational drug risankizumab in a pediatric population with moderate to severe plaque psoriasis. Subjects that meet all eligibility criteria will be randomized 2:1 to receive either risankizumab or ustekinumab, an active control. Both drugs will be injected subcutaneously (underneath the skin). At Week 16, subjects receiving ustekinumab or who are unresponsive to risankizumab, will be switched to or continue to receive risankizumab. Subjects that are responsive to risankizumab at Week 16, will be re-randomized 1:1 to continue risankizumab or withdraw from the study drug. Subjects randomized to withdraw will receive no study drug until a flare occurs, after which they will enter a 16-week re-treatment study period.
  • Compensation will be provided

Hidradenitis Suppurativa 

Please check back for upcoming hidradenitis suppurativa studies 

Vitiligo

Please contact Dr. Caroline Porter for more information regarding ongoing vitiligo studies

Email: portecar@musc.edu

Phone: 843-876-0110